已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

A fully chimeric IgG antibody for ROR1 suppresses ovarian cancer growth in vitro and in vivo

体内 抗体 卵巢癌 体外 癌症研究 ROR1型 受体酪氨酸激酶 化学 癌症 医学 生物 受体 免疫学 内科学 生物化学 生长因子 血小板源性生长因子受体 生物技术
作者
Zhengna Yin,Yuan Mao,Ningzhi Zhang,Yiping Su,Jin Zhu,Hua Tong,Huilin Zhang
出处
期刊:Biomedicine & Pharmacotherapy [Elsevier]
卷期号:119: 109420-109420 被引量:9
标识
DOI:10.1016/j.biopha.2019.109420
摘要

Over-expression of Receptor-tyrosine-kinase-like Orphan Receptor 1 (ROR1) in cancer cells has been reported in the context of several tumors (including ovarian cancer) and is associated with poor prognosis. The aim of this study was to construct a fully chimeric anti-ROR1 IgG antibody (ROR1-IgG) and investigate its antitumor activity against ovarian cancer cells, bothin vitro and in vivo. A fully chimeric anti-ROR1 IgG antibody (ROR1-IgG) eukaryotic expression vector was constructed and ROR1-IgG antibody was expressed in CHO cells. The characteristics of ROR1-IgG were investigated by ELISA, SPR, Western blotting, FACS and fluorescence staining analyses. CCK8 and wound healing assays were performed to determine inhibition and migration capacity of ovarian cancer cells after treatment with ROR1-IgGin vitro. Further, the antitumor activity of ROR1-IgG was assessed in vivo using tumor-mice xenograft model. The results showed that ROR1-IgG could specifically bind to ROR1-positive cells (HO8910 and A2780) with a high affinity. Functional studies revealed that ROR1-IgG inhibited the malignant behavior of ROR1-positive cells (HO8910 and A2780) in a time- and dose-dependent manner. These effects were not observed in ROR1-negative lose386 cells. The tumor inhibition rates following treatment with low, medium, and high concentrations of ROR1-IgG were approximately 47.72%, 53.79%, and 60.51%, respectively. In addition, the expression of Bcl-2 was obviously reduced while that of Bax was distinctly elevated in xenografts. Collectively, our findings suggest that ROR1-IgG may be a novel therapeutic agent for patients with ROR1-positive ovarian cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乐乐应助hao采纳,获得10
刚刚
小航完成签到 ,获得积分10
1秒前
2秒前
没有昵称完成签到 ,获得积分10
3秒前
15秒前
16秒前
16秒前
IIIKERUI发布了新的文献求助10
21秒前
谨慎颜演完成签到 ,获得积分10
23秒前
IIIKERUI完成签到,获得积分10
29秒前
30秒前
木沂完成签到 ,获得积分10
31秒前
39秒前
凝夜完成签到 ,获得积分10
39秒前
清脆的夜云完成签到,获得积分10
40秒前
aiiLuX完成签到 ,获得积分10
41秒前
xujiejiuxi发布了新的文献求助10
44秒前
Dawn完成签到 ,获得积分10
47秒前
安琪发布了新的文献求助10
47秒前
科研通AI2S应助GongZH采纳,获得10
48秒前
48秒前
54秒前
斯文败类应助Troutuatua采纳,获得10
56秒前
杳鸢应助科研通管家采纳,获得10
57秒前
VDC应助科研通管家采纳,获得20
57秒前
嗯哼应助科研通管家采纳,获得20
58秒前
VDC应助科研通管家采纳,获得20
58秒前
58秒前
杳鸢应助科研通管家采纳,获得10
58秒前
李健应助科研通管家采纳,获得10
58秒前
58秒前
58秒前
852应助科研通管家采纳,获得10
58秒前
明亮巨人完成签到 ,获得积分10
58秒前
1分钟前
1分钟前
3kou完成签到 ,获得积分10
1分钟前
TTK完成签到,获得积分10
1分钟前
Troutuatua发布了新的文献求助10
1分钟前
残月下的樱花完成签到,获得积分10
1分钟前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Semiconductor Process Reliability in Practice 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 600
GROUP-THEORY AND POLARIZATION ALGEBRA 500
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3234488
求助须知:如何正确求助?哪些是违规求助? 2880839
关于积分的说明 8217229
捐赠科研通 2548429
什么是DOI,文献DOI怎么找? 1377749
科研通“疑难数据库(出版商)”最低求助积分说明 647959
邀请新用户注册赠送积分活动 623314